|  |
| --- |
| **SUPPLEMENTARY TABLE 1.** **Cost estimates used in the Markov models.** |
| **Variable** | **Cost** |
| Monthly cost for patient with IBD in clinical “remission”  | $1,105 a |
| Outpatient urgent care visit | $110 b |
| ED visit:  | $1,311 b |
|  ED physician—initial consult | $177 |
|  ED facility fee | $505 |
|  Routine venipuncture | $3 |
|  Complete blood count with differential | $8 |
|  Comprehensive metabolic panel | $11 |
|  C-reactive protein | $5 |
|  Erythrocyte sedimentation rate | $3 |
|  Fecal calprotectin | $20 |
|  Lactate | $12 |
|  CT scan (assumes 75% of ED visits had CT scan):  | $567=0.75\*($374+$382) |
|  Radiologist fee | $374 |
|  Radiology facility fee | $382 |
| Hospitalization:  | $13,514 b |
|  Hospitalization with length of stay of 5 days | $12,073 |
|  Internist—initial consult | $206 |
|  Internist­—follow-up visit x4 days | $296 |
|  Gastroenterologist—initial consult | $206 |
|  Gastroenterologist—follow-up visit x4 days | $296 |
|  Gastroenterologist—fee for colonoscopy  | $209 |
|  Anesthesiology—fee for colonoscopy | $155 |
|  Pathology—fee for colon biopsies | $73 |
| CT, computed tomography; ED, emergency department; IBD, inflammatory bowel disease.Note: All cost estimates were from the third-party payer perspective and were updated to 2020 U.S. dollars by using the Consumer Price Index inflation calculator. a Estimate includes office visits, endoscopy, pathology, radiology, medications, and other outpatient services as reported by Park KT et al. (Am J Gastroenterol2016;111:15–23) and Park KT et al. (Inflamm Bowel Dis 2020;26:1–10). b Costs for physician services, procedures, and lab tests were obtained from the 2020 American Medical Association Current Procedural Terminology codebook and the 2020 Medicare Physician Fee Schedule. Costs for hospital admissions were obtained from the 2017 Healthcare Cost and Utilization Project database by searching for pertinent IBD ICD-10 codes. Facility fees were obtained from the 2020 Hospital Outpatient Prospective Payment System database. |

|  |
| --- |
| **SUPPLEMENTARY TABLE 2.** **Comparisons among sites where interventions were associated with cost savings in >75%, 25%–75%, and <25% of 1,000 Monte Carlo simulations.** |
| **Variable** | **Sites where** **interventions were associated with** **cost savings in** **>75% of simulations****(n=12)** | **Sites where** **interventions were associated with** **cost savings in** **25%–75% of simulations****(n=6)** | **Sites where** **interventions were associated with** **cost savings in** **<25% of simulations****(n=5)** | **P-value** |
| Clinic setting: |  |  |  | .40 a |
|  Academic | 8 (67%) | 2 (33%) | 3 (60%) |  |
|  Community | 4 (33%) | 4 (67%) | 2 (40%) |  |
| Number of clinical care process changes | 6 [3-7] | 5 [4-7] | 4 [2-6] | .11 b |
| Attendance rate at monthly IBD Qorus™ BTS Collaborative webinars  | 93% [60%-100%] | 87% [73%-100%] | 87% [33%-100%] | .45 b |
| IHI site assessment score | 3.0 [2.0-3.0] | 2.8 [2.0-3.0] | 2.5 [2.0-2.5] | .10 b |
| BTS, Breakthrough Series; IBD, inflammatory bowel disease; IHI, Institute of Healthcare Improvement.Data are presented as n (%) or median [range].a P-value from chi-squared test.b P-value from Kruskal-Wallis test. |

|  |
| --- |
| **SUPPLEMENTARY TABLE 3.** **Budget impact model incremental PMPM cost estimates of the intervention versus baseline periods for each site.** |
| **Site** | **Incremental PMPM cost** |
| All sites | –$2.74 ($0.25) |
| 1 | –$18.67 ($2.47) |
| 2 | –$17.21 ($2.05) |
| 3 | –$11.65 ($1.31) |
| 4 | –$10.10 ($1.63) |
| 5 | –$8.36 ($1.81) |
| 6 | –$6.15 ($2.91) |
| 7 | –$5.98 ($2.07) |
| 8 | –$4.18 ($0.44) |
| 9 | –$4.18 ($1.26) |
| 10 | –$3.63 ($2.08) |
| 11 | –$2.13 ($0.88) |
| 12 | –$1.19 ($1.25) |
| 13 | –$0.91 ($1.50) |
| 14 | –$0.69 ($1.26) |
| 15 | –$0.64 ($1.53) |
| 16 | –$0.34 ($1.87) |
| 17 | $0.46 ($2.89) |
| 18 | $0.98 ($1.92) |
| 19 | $1.89 ($1.47) |
| 20 | $6.51 ($3.13) |
| 21 | $7.47 ($0.92) |
| 22 | $7.70 ($1.89) |
| 23 | $8.41 ($2.57) |
| PMPM, per-member per-month; SD, standard deviation.Data are presented as mean incremental PMPM (SD) costs of the intervention versus baseline periods for all 1,000 Monte Carlo simulations. |